Focused On-demand Library for Complex III assembly factor LYRM7

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q5U5X0

UPID:

LYRM7_HUMAN

Alternative names:

LYR motif-containing protein 7

Alternative UPACC:

Q5U5X0; A8MPQ9; Q86Y68

Background:

Complex III assembly factor LYRM7, also known as LYR motif-containing protein 7, plays a crucial role in mitochondrial function. It acts as an assembly factor necessary for the incorporation of the Rieske Fe-S protein UQCRFS1 into the cytochrome b-c1 complex within the mitochondrial matrix. This process is vital for mitochondrial respiratory chain efficiency.

Therapeutic significance:

Given its pivotal role in mitochondrial complex III deficiency, nuclear type 8, understanding the function of LYRM7 could pave the way for innovative treatments. This disease manifests through a spectrum of symptoms, including mitochondrial encephalopathy and liver dysfunction, highlighting the therapeutic potential of targeting LYRM7.